The Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year ago. Profit per share beat Wall Street forecasts by a penny.
Excluding special charges, WellPoint’s profit fell 2 percent to $524.7 million in the fourth quarter from $536 million in the fourth quarter of 2009. But earnings per share improved thanks to stock buybacks.
Eli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease, but so far analysts are unimpressed.
Chris Sears is a health care and employee-benefits attorney at Ice Miller LLP in Indianapolis. He spoke about how employers are sizing up health insurance reforms that hit in 2014, which would set up government-subsidized insurance as a new option for workers but also would penalize most employers if they stop sponsoring employee health benefits.
Over the past 10 years, Purdue University has built Discovery Park into a thriving research and business incubation center, launching more than 30 companies and hosting dozens more. Now Purdue will spend more than $164 million to construct a Life and Health Sciences Quadrangle next to Discovery Park.
Supreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against Eli Lilly’s Icos subsidiary.
Hoosier Village Retirement Center in Zionsville announced plans Monday morning for a $32 million project that will expand its campus and allow the center to add 50 full-time workers.
The local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent on the process for making the active ingredient.
Eli Lilly and Co.’s Amyvid isn’t ready to be approved to detect Alzheimer’s-related deposits in the brain, according to FDA advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results of brain scans are read consistently, they said.
A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical designed to help screen for Alzheimer's disease could be useful pending additional study and training for physicians.
The state’s principal fund investing in high-tech companies has reached a milestone—for the first time recouping all the money it granted an emerging company, and then some.
A federal judge in Los Angeles ruled Wednesday that Carmel-based Conseco Life Insurance Co. may not follow through with a plan to raise policy rates for more than 50,000 mostly elderly policyholders.
Fourth quarter helps to bolster 2010 deal-making.
Conditions are ripe for a barrage of mergers and acquisitions to take place this year.
Alecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave to become president of Mills College in California on July 1.
State budget director Adam Horst said he misspoke when he told the State Budget Committee last week that Daniels&’ proposal would eliminate Medicaid coverage for hearing aids.
ParaPRO LLC’s treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
State Health Commissioner Greg Larkin says much of Indiana lacks the access to hospital trauma centers needed to treat victims of attacks like the one in Tucson that left U.S. Rep. Gabrielle Giffords of Arizona critically injured.
Clarian Health, which is set to change its name to Indiana University Health on Jan. 24, is relying on the academic expertise of its downtown Indianapolis hospitals to pull in patients from a wider swath of the state and the nation.
Eli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
